Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Aug;26(8):1671-1678.
doi: 10.3201/eid2608.201423. Epub 2020 May 29.

Investigation and Serologic Follow-Up of Contacts of an Early Confirmed Case-Patient with COVID-19, Washington, USA

Case Reports

Investigation and Serologic Follow-Up of Contacts of an Early Confirmed Case-Patient with COVID-19, Washington, USA

Victoria T Chu et al. Emerg Infect Dis. 2020 Aug.

Abstract

We describe the contact investigation for an early confirmed case of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in the United States. Contacts of the case-patient were identified, actively monitored for symptoms, interviewed for a detailed exposure history, and tested for SARS-CoV-2 infection by real-time reverse transcription PCR (rRT-PCR) and ELISA. Fifty contacts were identified and 38 (76%) were interviewed, of whom 11 (29%) reported unprotected face-to-face interaction with the case-patient. Thirty-seven (74%) had respiratory specimens tested by rRT-PCR, and all tested negative. Twenty-three (46%) had ELISA performed on serum samples collected ≈6 weeks after exposure, and none had detectable antibodies to SARS-CoV-2. Among contacts who were tested, no secondary transmission was identified in this investigation, despite unprotected close interactions with the infectious case-patient.

Keywords: 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; contact tracing; coronavirus; coronavirus disease; respiratory infections; serology; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case-patient investigation and contact identification during the investigation of an early confirmed US COVID-19 case, Washington, USA, 2020. The case-patient was asymptomatic when he arrived home from Wuhan, China. The next day, he developed a cough (day 1), followed by chills (day 2) and a subjective fever (day 3). When he arrived at the urgent care clinic (day 4), he was given a facemask and sat in the waiting room for ≈20 minutes. He was evaluated in a standard examination room, and received a chest radiograph in a radiology room down the hallway from the exam room. The case-patient was identified as meeting the Centers for Disease Control and Prevention (CDC) criteria at the time for a person under investigation for COVID-19, and specimens (nasopharyngeal and oropharyngeal swabs and serum samples) were collected for testing (6). He was clinically stable and discharged home pending SARS-CoV-2 test results. When COVID-19 was confirmed (day 5), the case-patient was admitted to a hospital for observation and isolation. After 11 days, he was discharged to home isolation until 2 negative sets of nasopharyngeal and oropharyngeal specimens were obtained >24 hours apart, in accordance with CDC guidance at the time (7). Persons exposed during transient interactions, such as restaurant waitstaff and persons encountered at the grocery store, were not considered community contacts. COVID-19, coronavirus disease.
Figure 2
Figure 2
Contact investigation flowchart of identified contacts, active monitoring, and participation in the enhanced contact investigation of an early confirmed US coronavirus disease case, Washington, USA, 2020. NP, nasopharyngeal; OP, oropharyngeal; PUI, person under investigation. *Includes contacts from whom specimens obtained for PUI testing. †Specimens were unable to be tested if blood could not be obtained (n = 5) or if the standard specimen requirements for testing were not met (n = 2).

Similar articles

Cited by

  • What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors.
    Koh WC, Naing L, Chaw L, Rosledzana MA, Alikhan MF, Jamaludin SA, Amin F, Omar A, Shazli A, Griffith M, Pastore R, Wong J. Koh WC, et al. PLoS One. 2020 Oct 8;15(10):e0240205. doi: 10.1371/journal.pone.0240205. eCollection 2020. PLoS One. 2020. PMID: 33031427 Free PMC article.
  • Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United States.
    Burke RM, Balter S, Barnes E, Barry V, Bartlett K, Beer KD, Benowitz I, Biggs HM, Bruce H, Bryant-Genevier J, Cates J, Chatham-Stephens K, Chea N, Chiou H, Christiansen D, Chu VT, Clark S, Cody SH, Cohen M, Conners EE, Dasari V, Dawson P, DeSalvo T, Donahue M, Dratch A, Duca L, Duchin J, Dyal JW, Feldstein LR, Fenstersheib M, Fischer M, Fisher R, Foo C, Freeman-Ponder B, Fry AM, Gant J, Gautom R, Ghinai I, Gounder P, Grigg CT, Gunzenhauser J, Hall AJ, Han GS, Haupt T, Holshue M, Hunter J, Ibrahim MB, Jacobs MW, Jarashow MC, Joshi K, Kamali T, Kawakami V, Kim M, Kirking HL, Kita-Yarbro A, Klos R, Kobayashi M, Kocharian A, Lang M, Layden J, Leidman E, Lindquist S, Lindstrom S, Link-Gelles R, Marlow M, Mattison CP, McClung N, McPherson TD, Mello L, Midgley CM, Novosad S, Patel MT, Pettrone K, Pillai SK, Pray IW, Reese HE, Rhodes H, Robinson S, Rolfes M, Routh J, Rubin R, Rudman SL, Russell D, Scott S, Shetty V, Smith-Jeffcoat SE, Soda EA, Spitters C, Stierman B, Sunenshine R, Terashita D, Traub E, Vahey GM, Verani JR, Wallace M, Westercamp M, Wortham J, Xie A, Yousaf A, Zahn M. Burke RM, et al. PLoS One. 2020 Sep 2;15(9):e0238342. doi: 10.1371/journal.pone.0238342. eCollection 2020. PLoS One. 2020. PMID: 32877446 Free PMC article.
  • Service evaluation of 'GP at Door' of accident and emergency services in Eastern England.
    Brainard J, Rice A, Hughes G, Everden P. Brainard J, et al. Prim Health Care Res Dev. 2025 Jan 10;26:e5. doi: 10.1017/S1463423624000707. Prim Health Care Res Dev. 2025. PMID: 39789962 Free PMC article.
  • When to test for COVID-19 using real-time reverse transcriptase polymerase chain reaction: a systematic review.
    Dos Santos PG, Vieira HCVS, Wietholter V, Gallina JP, Andrade TR, Marinowic DR, Zanirati GG, da Costa JC. Dos Santos PG, et al. Int J Infect Dis. 2022 Oct;123:58-69. doi: 10.1016/j.ijid.2022.06.037. Epub 2022 Jun 26. Int J Infect Dis. 2022. PMID: 35760382 Free PMC article.
  • Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland.
    Dupraz J, Butty A, Duperrex O, Estoppey S, Faivre V, Thabard J, Zuppinger C, Greub G, Pantaleo G, Pasquier J, Rousson V, Egger M, Steiner-Dubuis A, Vassaux S, Masserey E, Bochud M, Gonseth Nusslé S, D'Acremont V. Dupraz J, et al. Open Forum Infect Dis. 2021 Mar 26;8(7):ofab149. doi: 10.1093/ofid/ofab149. eCollection 2021 Jul. Open Forum Infect Dis. 2021. PMID: 34307723 Free PMC article.

References

    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
    1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al.; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–36. 10.1056/NEJMoa2001191 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel; 2020. [cited 2020 Mar 30]. https://www.fda.gov/media/134922/download
    1. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3. 10.1126/science.abb2507 - DOI - PMC - PubMed
    1. Trivedi S, Miao C, Al-Abdallat MM, Haddadin A, Alqasrawi S, Iblan I, et al. Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection. J Med Virol. 2018;90:367–71. 10.1002/jmv.24948 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources